Interventional oncology firm Delcath's Q2 revenue beats estimates
Overview
Delcath Q2 2025 revenue grows significantly, beating analyst expectations, per LSEG data
Net income turns positive at $2.7 mln, compared to loss last year
Co activates three new U.S. centers, expanding treatment network
Outlook
Delcath projects 2025 revenue of $93 mln to $96 mln
Company expects 2025 gross margins between 83% and 85%
Delcath anticipates positive adjusted EBITDA each quarter in 2025
Result Drivers
HEPZATO SALES - Significant revenue growth driven by HEPZATO KIT sales, reaching $22.5 mln, up from $6.6 mln in Q2 2024
NEW CENTERS - Activation of three new U.S. centers, increasing total to 20 active centers, supporting revenue growth
R&D EXPANSION - Increased R&D expenses due to clinical team expansion and new trial initiations for metastatic colorectal and breast cancer
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $24.16 mln | $22.80 mln (6 Analysts) |
Q2 EPS |
| $0.07 |
|
Q2 Net Income |
| $2.70 mln |
|
Q2 Gross Profit |
| $20.84 mln |
|
Q2 Operating Expenses |
| $18.25 mln |
|
Q2 Operating Income |
| $2.59 mln |
|
Press Release: ID:nBwc2VhvRa
